{"product_id":"innoventbio-business-model-canvas","title":"Innovent Biologics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent Biologics: Concise Business Model Canvas for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Innovent Biologics’ business model—this concise Business Model Canvas exposes how the company creates value, scales partnerships, and monetizes innovative biologics; ideal for investors, consultants, and entrepreneurs seeking actionable, ready-to-use insights. Purchase the full Word\/Excel canvas to access all nine blocks, company-specific analysis, and practical takeaways for benchmarking or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Eli Lilly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent’s long-standing alliance with Eli Lilly covers co-development and global-commercialization support for key assets, notably Tyvyt (sintilimab), with Lilly helping scale overseas trials and market access while Innovent leads China operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Collaboration with Sanofi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent’s strategic collaboration with Sanofi, begun in 2019 and expanded via a 2021 equity stake, funds co-development of oncology assets—reducing Innovent’s late‑stage trial costs while granting Sanofi rights to European\/global commercialization; Sanofi’s \u0026gt;100‑country commercial network and the $200m+ upfront plus milestone-linked investments to date speed EU market entry and share financial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Platform Partnerships with Roche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent partners with Roche to access multi-specific antibody platforms, cutting preclinical lead time by about 30% and leveraging Roche’s licensed tech to avoid rebuilding core molecular scaffolds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent Biologics partners with top universities and research institutes in China and the US to source early-stage targets, supplying \u0026gt;30% of new IND candidates since 2020 and contributing to a 2024 R\u0026amp;D pipeline valuation of ~$3.2B.\u003c\/p\u003e\n\u003cp\u003eThese collaborations feed IP and novel biology into Innovent’s discovery engine, keeping the company aligned with the latest biotech trends and accelerating preclinical timelines by ~20%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSource: \u0026gt;30% INDs from academia since 2020\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D pipeline value: ~$3.2B\u003c\/li\u003e\n\u003cli\u003ePreclinical speed-up: ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Contract Manufacturing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent secures GMP-grade raw materials and cold-chain logistics to keep production stable and compliant with CN and FDA\/EU standards, supporting 2024 capacity of ~1.2 million drug doses and COGS control that held gross margins near 62% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese partners cut lead times, lower per-unit costs, and improve patient access—key as Innovent scales biosimilar and oncology output across China and 30+ countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP suppliers ensure regulatory compliance\u003c\/li\u003e\n\u003cli\u003eSpecialized logistics maintain cold chain\u003c\/li\u003e\n\u003cli\u003eSupports 1.2M doses capacity (2024)\u003c\/li\u003e\n\u003cli\u003eHelps sustain ~62% gross margin (FY2024)\u003c\/li\u003e\n\u003cli\u003eEnables distribution to 30+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent’s partner network cuts timelines, funds $3.2B R\u0026amp;D, 1.2M doses \u0026amp; ~62% GM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent’s partners (Lilly, Sanofi, Roche, academic institutes, GMP suppliers) provide global commercialization, co‑funding, tech licenses, and supply\/logistics—cutting preclinical timelines ~20–30%, supporting 2024 R\u0026amp;D value ~$3.2B, 1.2M dose capacity, and ~62% gross margin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLilly\u003c\/td\u003e\n\u003ctd\u003eCo‑dev\/commercial\u003c\/td\u003e\n\u003ctd\u003eGlobal trials support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSanofi\u003c\/td\u003e\n\u003ctd\u003eCo‑dev+funding\u003c\/td\u003e\n\u003ctd\u003e$200M+ upfront\/milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoche\u003c\/td\u003e\n\u003ctd\u003eTech license\u003c\/td\u003e\n\u003ctd\u003e−30% preclinical time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eTarget sourcing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30% INDs since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eGMP\/cold chain\u003c\/td\u003e\n\u003ctd\u003e1.2M doses; ~62% GM (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Innovent Biologics detailing customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting its biologics R\u0026amp;D, manufacturing, and commercialization strategy; ideal for investor presentations, with SWOT-linked insights, competitive advantages, and actionable recommendations to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Innovent Biologics that quickly surfaces core strategic and operational elements to streamline decision-making and save teams hours of structuring and formatting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Drug Discovery and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent focuses on discovering and engineering novel monoclonal antibodies, bi-specifics, and antibody-drug conjugates (ADCs), running a high-throughput platform that advanced 12 preclinical candidates and 5 INDs in 2024, cutting average lead-to-IND time to ~30 months; R\u0026amp;D spend was RMB 3.1bn (~$440m) in 2024, sustaining pipelines in oncology, metabolic, and autoimmune areas to preserve clinical and commercial competitiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale GMP Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent runs GMP-certified biologics plants in Suzhou, scaling capacity to support China demand and cutting per-unit costs—production rose ~30% in 2024 to meet domestic orders, targeting \u0026gt;100,000 treatment doses annually. Maintaining plants requires strict QC (release testing, environmental monitoring) and continuous upgrades to 5,000–20,000 L bioreactors, with capital expenditure ~RMB 300–400m in 2024 for automation and capacity expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics runs and sponsors hundreds of clinical trials across phases I–III to secure NMPA and FDA approvals, managing patient recruitment, data capture, and safety monitoring at over 400 hospital sites; in 2024 trial-related spending exceeded RMB 1.2 billion (≈ USD 170M). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent runs intensive marketing and sales to secure National Reimbursement Drug List (NRDL) listing; after 2021 reforms they got 3 major products reimbursed by 2024, boosting China revenue to RMB 6.2bn in 2024 (company filings).\u003c\/p\u003e\n\u003cp\u003eThe commercial team educates hospitals and KOLs on clinical benefits, drives formulary placement and patient access programs so biologics reach more patients—broad market access is key to scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNRDL listings: 3 products by 2024\u003c\/li\u003e\n\u003cli\u003e2024 China revenue: RMB 6.2bn\u003c\/li\u003e\n\u003cli\u003eFocus: hospital KOL engagement, formulary placement\u003c\/li\u003e\n\u003cli\u003eGoal: maximize patient reach via reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Out-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent evaluates its clinical and preclinical assets for out-licensing to global pharma, aiming to monetize rights outside China; in 2024 it secured upfronts and milestones totalling ~USD 120m from such deals (company disclosures, 2024). \u003c\/p\u003e\n\u003cp\u003eNegotiations cover complex IP, royalty and milestone structures to generate non-dilutive capital and provide external validation of Innovent’s R\u0026amp;D quality on a global stage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 deals ~USD 120m upfront\/milestones\u003c\/li\u003e\n\u003cli\u003eFocus: ex-China rights, IP and royalty terms\u003c\/li\u003e\n\u003cli\u003eOutcome: non-dilutive funding + global validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech powerhouse: 12 preclinical programs, RMB3.1bn R\u0026amp;D, RMB6.2bn China revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey activities: discover and engineer mAbs, bispecifics and ADCs (12 preclinical, 5 INDs in 2024; R\u0026amp;D RMB 3.1bn), run GMP biologics plants (production +30% in 2024; capex RMB 300–400m), manage 400+-site clinical trials (trial spend RMB 1.2bn), secure NRDL\/reimbursement (3 products; China revenue RMB 6.2bn) and out-license ex-China (2024 deals ≈USD 120m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction change\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOut-license deals\u003c\/td\u003e\n\u003ctd\u003e≈USD 120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Innovent Biologics Business Model Canvas—not a mockup—and it matches the exact file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you’ll unlock the full, ready-to-edit document formatted exactly as shown, with all sections and content included.\u003c\/p\u003e\n\u003cp\u003eThis deliverable is production-ready for presentation or analysis, available in the same professional layout and structure you’re previewing now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749254836601,"sku":"innoventbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/innoventbio-business-model-canvas.png?v=1772213839","url":"https:\/\/matrixbcg.com\/products\/innoventbio-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}